1. Introduction {#sec1}
===============

Health and the economy are related intrinsically. The purpose of the studies on the costs of diseases is describing them, estimating costs, comparing established programs, and projecting these costs based on clinical, demographic, epidemiological, and technological factors. In fact, over the past decade, there has been a growing number of studies, which are presumed to be valuable decision tools, because the limited amount of resources must be used rationally and efficiently as not to miss opportunities to improve overall population health \[[@B1]\].

In neurodegenerative diseases, such as Parkinson\'s disease (PD), whose prevention is still impossible, the burden borne by society, whether it is financial, social, or even psychological, is often heavy. Being the second most prevalent neurodegenerative disease worldwide, it generally affects individuals between 40 and 50 (late-onset PD) \[[@B2], [@B3]\], compromising their productive life and aging. As such, research needs to be directed to reducing their costs.

Studies on disease costs may have several approaches, such as economic assessment, epidemiological design, or even type of cost involved, as well as the viewpoint of defining resource use strategies. The diversity in methods is a significant factor why cost estimates differ between studies, opening the discussion about which public policies are most appropriate for PD.

This systematic review provides introductory concepts on the types of studies on costs and analyzes results in selected articles critically, highlighting the benefits and limitations of their methods. Moreover, this study identifies the most common studies regarding DP costs worldwide over the past 10 years, showing possibilities for studies being carried out in Brazil, where there is a lack of this type of analysis because most studies only involve the clinical aspects of the disease.

2. Methodology {#sec2}
==============

In March 2016, two*online* bibliographic information services were accessed---SCOPUS and PubMed---with the aim of selecting original articles about the cost of PD over the past decade.

The following terms were used for access:*(parkinson disease) AND TITLE-ABS-KEY (economics) OR TITLE-ABS-KEY (costs of illness) OR TITLE-ABS-KEY (health expenditures) OR TITLE-ABS-KEY (cost effectiveness analysis) OR TITLE-ABS-KEY (cost benefit analysis) OR TITLE-ABS* - CUT (cost utility analysis) OR TITLE-ABS-KEY (cost minimization analysis) OR TITLE-ABS-KEY (direct costs) OR TITLE-ABS-KEY (CB costs) OR TITLE-ABS-KEY (out of pockets) AND DOCTYPE (air OR re) AND PUBYEAR \> 2004 AND (LIMIT-TO (LANGUAGE, "English")) AND (LIMIT-TO (DOCTYPE, "air")).

This method identified 522 papers. The inclusion criterion was that articles refer to costs related to this disease in general and/or regarding the use of medication. Papers that compared procedures and/or medicines, dealt with specific therapies, as well as PD surgeries, or were related to patient caregivers or already selected papers but were neither applicable to the research nor available to access were excluded. Revisions were also not selected (380 papers were excluded because of the title, for not being compatible, having been duplicated, and/or being reviews). Once the first levels of inclusion were satisfied, 142 papers were selected for reading the*abstract*. Although 35 of these had a suggestive title, that is, they did not tackle general costs of disease exclusively, 107 were separated for complete reading, and 30 met the criteria for research ([Figure 1](#fig1){ref-type="fig"}).

2.1. Basic Concepts of Health Studies {#sec2.1}
-------------------------------------

The determination of the costs of a disease facilitates learning what its burden to society is, assessing its degree of efficiency, and understanding how the market tends to organize itself regarding certain values \[[@B4]\].

### 2.1.1. Economic Assessment {#sec2.1.1}

The basic function of any economic assessment is to identify, measure, value, and compare the costs and consequences of alternative proposals \[[@B4]--[@B8]\].

In this case, four techniques are possible ([Table 1](#tab1){ref-type="table"}):

*(1) Cost-Minimization.* Cost-minimization is the least used technique, because it only compares costs of interventions that produce the same outcomes with different costs. For chronic diseases, such as PD, there are no studies using this type of analysis.

*(2) Cost-Effectiveness.* Cost-effectiveness is the technique most used in literature, which assesses the impact of different alternatives that bring better results with lower costs; these are always comparative and explicit and designed to select the best option to achieve what is perceived in clinical practice.

*(3) Cost-Benefit.* This analysis determines whether a new health technology or intervention generates net benefits to society. However, due to its difficulty, complexity, and controversies in valuing human life and certain health conditions in monetary terms, this analysis is rarely found in the literature.

*(4) Cost-Utility.* This analysis assesses the impacts on survival and quality of life, which are determining criteria to judge the effects of strategies in health care, that is, the level of well-being and preferences of the individual.

### 2.1.2. Study Designs {#sec2.1.2}

The epidemiological study designs define how the research will be performed in relation to adopted method \[[@B9]--[@B13]\]. The most discussed study designs in PD research are as follows ([Table 2](#tab2){ref-type="table"}).

*(1) Prevalence and Incidence.* The prevalence estimates the number of deaths, hospitalizations, prevention, and research attributable to a disease in a given period (usually a year), to subsequently estimate the costs incurred by these consequences. Incidence refers to the number of new cases in a predefined period, and it foresees the associated costs from the onset of the disease until its disappearance (usually cure or death), through a rough projection of the flow of these values.

Studies on prevalence display greater results than incidence ones, for diseases are usually long-term sequelae, as is the case of PD, and they are of great importance in planning specific policies on certain diseases when their economic burden was underestimated. Therefore, they can identify the main components of current expenses and uncharged resources.

*(2) Top-Down and Bottom-Up.  Top-down* approaches are normally used in prevalence studies, when the expenses of a disease are widely known from national or regional statistics. In*bottom-up* studies, cost estimates are more detailed. The data depend on the scope of the study, and they are intrinsically related to the unit costs of inputs used, through interviews, questionnaires or chart review, and assessment of individual cost. The average cost per person is then obtained by means of the number of times the service was used and the number of people with the disease. Although*bottom-up* studies are more complete when it comes to resources and more precise regarding patient selection, they run a high risk of double counting costs (e.g., if a patient has more than one disease and costs of comorbidities are confused and/or grouped). The majority of studies with PD adopt this approach.

*(3) Prospective and Retrospective Approaches.* There is a temporal relationship, where in prospective studies the relevant events have not happened yet, that is, studying the patient over time, formalizing a system of data collection focused on the purpose of the research, such as questionnaires designed specifically for patients and/or their caregivers, where everything is recorded in "real time." In retrospective studies, all events had already occurred when the study was initiated. They are usually employed in long-term chronic diseases, as is the case of PD. In this case, research efficiency can only be possible with enough observational datasets. It would be best if the data were stored electronically to minimize memory bias due to omission of facts or values.

*(4) Econometric Approaches.* Econometric approaches estimate differences between groups. One of the groups has the disease and the other does not; however, both have the same characteristics, which are assessed by several regression analyses involving demographic factors such as sex, age, marital status, ethnicity, relationship between patient and caregiver, housing, and duration of the disease.

*(5) Markov Models.* Markov models are used in several studies of chronic diseases, when patients are studied over time, and they are stratified according to disease scale. In the case of PD, the scale of Hoehn and Yahr (it assesses the degree of disability due to the disease in scores) is key to building this model. These are typically prospective studies, proposing cost increases with disease severity.

Several approaches may be featured in the same study; that is, we may have a retrospective, prevalent, and*bottom-up* study, for instance, because its purpose, most of the time, is to maximize the content of information, contributing to enriching knowledge.

### 2.1.3. Classification of Costs {#sec2.1.3}

The costs of a disease are typically stratified as follows \[[@B4], [@B7], [@B10], [@B14]\] ([Table 3](#tab3){ref-type="table"}).

*(1) Direct Costs.* Direct costs are related to the disease and its equation; their charges may concern public administration, insurance companies, the patient, the patient\'s family, or even a combination of all or some of these determinants. The estimates of direct costs associated with chronic diseases are higher than those associated with acute and communicable diseases, on the condition that better treatments and methods of prevention are adopted. This group can be divided into direct medical costs and nonmedical ones, although not all studies adopt this division.

*(2) Indirect Costs.* Indirect costs refer to the loss of income and/or productivity; they are caused by disease. Additionally, they can incur costs to both the patient and the employer. Depending on the disease, this loss may be partial, temporary, or permanent, and it may be restricted to the patient and/or caregiver (as in the case of advanced stage PD), frequently leading to early retirement. If there is a possibility of returning to regular activities, this disease may not occur on the same productivity level as before, or lead to frequent absences (absenteeism), incurring additional costs, such as loss of promotions.

*(3) Intangible Costs.* Intangible costs are virtually impossible to measure, since they incur psychological and psychosocial costs imposed to the patients, their family, and acquaintances due to the disease, as well as pain, behavioral changes, and everyday activities. They depend on the perception that the patient\'s health problems lead to social consequences, such as isolation.

*(4) Personal Costs.* Personal costs are the costs borne by the patient and/or their family and friends due to consultations with health professionals, medication, laboratory tests, domestic adjustments, locomotion resources, and the need for home care. Depending on the country, these costs, also called copayments, are borne by the government, health insurance, or religious or private health institutions. Sometimes, these payments are also designated as direct costs because they are associated with the disease. They may be redeemable or not, implying an additional expense to the patient, who has to spend a certain amount of money in advance.

### 2.1.4. Perspectives {#sec2.1.4}

Who bears the costs related to the program defines which costs are included for analysis \[[@B6], [@B7], [@B10]\] ([Table 4](#tab4){ref-type="table"}).

*(1) Industry (Human Capital).* The industry bears the costs due to absenteeism or loss of productivity, and early retirement due to the disease.

*(2) Society.* A more comprehensive perspective considers all costs related to the program, regardless of who will pay the expenses (patient, government, or insurance companies). This approach is thought to be the most appropriate to support health-related decisions. Most research on PD addresses this perspective, although some studies include more than one viewpoint.

*(3) Patients and Their Family.* Costs are borne by the patient concerning appointments, transport used for his treatment, purchase of medication, expenses with caregivers, domestic changes, and so on.

*(4) Programs, Public Health, and/or Insurance Companies.* When there is a need to identify all the inputs related to the disease, for which monetary value explains the base period and the form of assessment used should be assigned, this perspective is highly likely to underestimate the cost of disease, especially when greater profit or lower production costs are targeted.

2.2. Studies on the Socioeconomic Impact of PD {#sec2.2}
----------------------------------------------

Although PD affects more than four million people worldwide \[[@B15]\], little is known about their progression rates, the costs of medical care, and the management of resources specific to this disease \[[@B16]\]. In Brazil, although its notification is not compulsory, unofficial data estimate 220,000 PD sufferers. Considering local records of patients with PD, in a study conducted in the city of Bambuí, Minas Gerais, it was found that 3% of the population above 64 had the disease, a result similar to the prevalence rates found in elderly studies in European and American countries and slightly above the rates in Eastern countries \[[@B17]\].

PD was considered among the most prevalent and costly diseases of the brain, being the fourth most expensive second study in 28 European countries \[[@B18]\]. However, the level of socioeconomic development, budget availability of health systems, and culture of each country or region determine research methodologies, which are directed to a subset of expenses, using only a few components and all expenditure resulting from a disease, which would be practically impossible. Therefore, there is no one method more or less appropriate for this type of study, as the costs of PD in all countries involved cannot be compared and the information cannot be simply transferred from one country to another without having any evidence to support the use of the data.

Over the past decade, there has been a significant increase in the number of papers related to costs of diseases. [Figure 2](#fig2){ref-type="fig"} shows the evolution for PD, between 2005 and February 2016, with a higher concentration between 2011 and 2013, triggered by the need to investigate the values involved in the cost of this disease. The demographic transition is a reality, and health managers need data that can enable their strategies towards public policies. The graph shows the 522 identified papers (125 Pubmed, 397 Scopus) and the 30 selected among them for this review.

3. Discussion {#sec3}
=============

The papers selected for this review are summarized in [Table 5](#tab5){ref-type="table"}. The PD cost may be very different from one country to another. Nonetheless, the monetary value of the year in which the study happened should be considered. All values were converted to US dollars (\$) and daily, quarterly, or half-yearly results were converted to annual. Only one article had values by period of life \[[@B19]\], and another took into consideration those 40 to 79 years of age \[[@B20]\].

Practically, all articles used the general costs of the disease, without naming the type of economic evaluation. Only one article \[[@B21]\] referred to the burden of disease as DALY (disability-adjusted life in years), suggesting the use of cost-utility.

Because there is no way of implementing measures so as to reduce new cases, the most appropriate model for PD costs may be developed from prevalence studies. They are conducted when diagnosis has already been established, obtaining ample results, and are to conduct than incidence ones, which demand rigorous criteria for diagnosis. In this review, we identified 20 papers that followed this line of research (see [Table 4](#tab4){ref-type="table"}).

The use of questionnaires, suggesting a bottom-up approach, is common practice found in the research reviewed here, although not all of them described the design. The unit value of the inputs used is more easily acquired than full reports obtained from large databases in top-down approaches, although at least six papers suggest the use of this approach for studying large samples \[[@B22]--[@B27]\].

Since it is a disease with long survival, retrospective studies are the most common for PD, despite the bias of memory that can be generated depending on the retroactive period. In reviewed articles, 12 authors (see [Table 4](#tab4){ref-type="table"}) opted for a prospective study with patient monitoring. Despite being lengthy and expensive, some studies used Markov models \[[@B19]\] or econometric studies \[[@B28], [@B29]\] with cohorts, for example.

The aforementioned chosen variables are related to the purpose of the study, but, in general, we observed that 20 (see [Table 4](#tab4){ref-type="table"}) out of 30 papers opted for the total cost of the disease, including direct, indirect, and/or personal costs. In one of the studies \[[@B20]\], however, indirect costs were only considered, from the perspective of insurance companies and human capital, whereas, in another \[[@B21]\], the aim was to evaluate intangible costs alone through lost years of life. Similarly, three studies concentrated only on medication costs \[[@B25], [@B30], [@B31]\].

Among direct costs, the most common variables analyzed in most studies were medication, hospitalizations, outpatient visits, auxiliary treatments, home care, transport, and special equipment. Not all studies divided the direct costs into medical and nonmedical ([Table 3](#tab3){ref-type="table"}). In one of the studies, even dental care provided to patients was assessed \[[@B29]\].

Regarding indirect costs, most studies are related to the patient and/or the caregiver in terms of loss of productivity, early retirement, and sick leaves (medical certificates). As for personal costs, they consider informal care, copayment treatments, drugs, and equipment.

The society costs are the most studied, the society being the most affected regarding allocation of resources. Only four studies assessed this prospect from the patient\'s point of view \[[@B27], [@B32]--[@B34]\].

Clarity is needed in the way data and/or results are expressed, which may generate uncertainty or confusion in the conclusion of a study. For instance, one of the studies \[[@B35]\] does not provide a clear cost of PD, and groups are very stratified and only the differences between them are highlighted. Moreover, albeit the many variables analyzed, important components were not assessed, such as auxiliary treatments. On the other hand, another study \[[@B20]\] does not enlist which direct cost components were used. As such, statistical analyses must be well established, so that other studies can be replicated if necessary. In this review, some studies did not provide that \[[@B25], [@B31], [@B36]\].

Many authors have chosen to direct certain types of costs towards one category, which reinforces the uniqueness of each study. One author \[[@B37]\] argued that informal care should be placed with indirect costs, but with direct nonmedical ones, based on the fact that if home care is not provided by the family, professional care would be needed.

The fact that the same cost component is classified in different categories can have a strong influence on the final results, not considering the values set by the inputs in each country. In a study conducted in Russia \[[@B37]\], for example, direct costs accounted for 67% of total costs, while indirect ones accounted for 33%. Besides, in a study in Singapore \[[@B38]\], direct costs were 38.5% and indirect ones 61.5% of the total cost. Another author states \[[@B39]\] that costs were distributed as 35.7% direct, 29.4% as direct nonmedical costs and 34.9% as indirect. In this study, we have verified that the value of consultation with a specialist in the Hungarian public health care system costs around \$7, while in the UK \[[@B33]\] this value is approximately \$225.

Issues related to health insurance also influence the comparison of studies greatly and must be considered. For example, in India, a study \[[@B36]\] revealed that only 7.4% of patients are covered by health insurance, and, unlike most studies reviewed, the cost of PD treatment is very low, at around \$707 per year, since most of the expenses are covered by the patients and their family. Conversely, in the UK \[[@B33]\], maintaining virtually the same research approach, a final value of around \$20,000 a year was calculated. In Japan, on the other hand \[[@B44]\], a study found a value of around \$6,000 per PD patient, where the health insurance covers 100% of the population. Depending on the patient\'s income or age, he/she contributes 10% to 30% to medical costs.

There are some other factors that certainly affect the results obtained: samples ranged from small cohorts (*n* = 12) \[[@B28]\] to large populations (*n* = 630,000) \[[@B22]\], some studies \[[@B41], [@B42]\] have excluded from their samples patients with advanced PD (Hoehn & Yahr 5), and others \[[@B19], [@B43]\] assessed not only PD, but also its complications and/or comorbidities.

Finally, with regard to the revised articles of this manuscript, we could suggest an instrument as a guideline to determine PD-related costs even though several methodologies and different variables could be taken into account for each particular scenario. Therefore, prospective studies would be the ideal methodology, but cross-sectional, retrospective ones, with a bottom-up approach from the perspective of society, could be more feasible. The questionnaire to obtain data could be divided into the following parts:Clinical, social, demographic, and economic issues of the patient;Medical and nonmedical direct costs;Indirect costs;Personal costs (including caregivers).

The most common variables found in the literature used to determine the costs of PD, depending on the scope of the study, are shown in [Table 6](#tab6){ref-type="table"}.

4. Conclusion {#sec4}
=============

The concepts mentioned in this review do not aim to finalize the discussion on health economics tackling the costs of neurodegenerative diseases, such as PD, but only to allow access to introductory concepts of these assessments, so that the reader can contextualize the articles analyzed here.

The very definition of studies on costs of disease suggests limitations, as the articles here reviewed display methodological heterogeneity regarding PD costs, and this variation is an important factor that should receive more attention in literature. Unlike Alzheimer\'s disease, which has a validated instrument to determine the costs of illness \[[@B51]\], PD presents considerable problems in its analysis, since evaluations and comparisons are made between individual studies. If there were a standardized and validated instrument, the data costs would be more reliable and transparent and there would be rational allocation of resources and better collection of data for cost analysis and efficacy.

We observed that there is no standardization of terminology used for the definition of costs, or even unanimity in the identification of categories because a variable can be found in different classifications, depending on the criterion used by the researcher, which may underestimate the total cost of the disease.

On the other hand, there is no one perfect research methodology covering a single answer for all solutions. Sometimes, certain types of studies are more appropriate than others. There are several limitations that must be discussed and related to, such as the methodological problems, and the validity of their assumptions can differ because they may introduce bias in analysis in favor of a variable, lack of interest in its assessment, or even lack of information. Therefore, researchers must be careful with the source of their data and the method used for performing the calculations, so that their research can be replicated and validated, since there is no specific instrument for the assessment of PD costs. A limitation also deals with the funding sources of studies, which may be from government sources, insurance companies, or pharmaceutical industries, for example, generating important biases that also need to be addressed. It is necessary to define useful metrics for public health and private ones for managers of health, employers, insurance companies, and even patients themselves, because, without this agreement, the work of researchers and the funds invested shall remain uncertain and inconsistent.

Nevertheless, if the evidence obtained is of good quality in terms of transparency, there is quality and credibility in the data completeness of the documentation. Overall, if they are relevant to health care \[[@B52]\], these studies contribute to a better allocation of resources that are not related to savings but evaluate the efficiency, effectiveness, and safety of interventions.

The age group that the PD affects, if well attended to, can experience "healthy aging," with a good quality of life and preserve its autonomy for longer, thus reducing its cost to the state and society.
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###### 

Types of economic evaluation and their main characteristics.

  Type of economic analysis   Costs      Advantages                                                                                         Disadvantages
  --------------------------- ---------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------
  Cost minimization (CMA)     Monetary   This technique only measures costs                                                                 It does not describe results, and it has little applicability to health
  Cost-effectiveness (CEA)    Monetary   It allows comparisons between health programs                                                      Difficulty in comparison of results
  Cost-benefit (CBA)          Monetary   This analysis allows comparisons between strategies because it works with the same monetary unit   Difficulty of valuing human life
  Cost-utility (CUA)          Monetary   This analysis considers the level of well-being and preferences of the individual                  The scales of measurement of quality are arbitrary

###### 

Main study designs on costs.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Approaches      Description                                                                                                                           Advantages                                                                                                     Disadvantages
  --------------- ------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------
  Prevalence      Frequency measure\                                                                                                                    Ample results\                                                                                                 Considered weak at estimating the risk of developing disease
                  It evaluates all existing cases in a given period                                                                                     Specific policy planning\                                                                                      
                                                                                                                                                        Fast study and recommended for chronic diseases                                                                

  Incidence       Frequency measure\                                                                                                                    Implementation of measures to reduce new cases\                                                                Not recommended for chronic diseases
                  Assesses the number of new cases in a given period                                                                                    It is used more for acute diseases, since it estimates the risk of developing the disease                      

  Top-down        It measures the proportion of a disease attributed to several risk factors. It involves a study directed from total to lower levels   When the scope of study is well understood                                                                     More comprehensive, it hampers the study on the details of the disease

  Bottom-up       Related to the unit costs of inputs used. It involves the study directed from individual levels to the total.                         More detailed                                                                                                  Risk of double counting

  Prospective     Temporal study, performed during disease. Probes the effect through the cause                                                         Used in chronic diseases                                                                                       Time-consuming and expensive

  Retrospective   Temporal study performed with preexisting data.\                                                                                      Quick and cheaper                                                                                              Risk of memory bias
                  Probes the cause through the effect                                                                                                                                                                                                                  

  Econometric     Comparison of groups                                                                                                                  Minor amount of data required\                                                                                 Long study, requiring that the control group be paired to the study group
                                                                                                                                                        Cost difference between the two populations                                                                    

  Markov models   Stochastic process\                                                                                                                   Dynamic model aiming at studying the transition from one stage to another, evaluating the costs of each step   Transition of stages is independent, without considering the previous one
                  Used in prospective studies. Patients stratified in stages of disease                                                                                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Classification of costs.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Types of costs      Description
  ------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Direct medical      Directly related to the disease. Hospitalization, medication, medical appointments, treatments, laboratory tests, and diagnosis

  Direct nonmedical   Directly related to the disease. Transport, domestic modifications, food

  Indirect            Loss of productivity: partial, temporary, or permanent\
                      They may affect the patient and/or caregiver\
                      Early retirement

  Intangible          Psychological and psychosocial and costs, difficult measurement

  Personal            Costs incurred by the patient and/or their family, when there is no support from private and/or public health care. Private consultations, medication, treatments, and domestic modifications. Linked with direct costs
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Description of the main perspectives used in cost studies.

  Perspective                  Description
  ---------------------------- -----------------------------------------------------------------------------------------------------------------------------
  Industry                     Related to human capital. Considers the individual as an investment target
  Society                      More common in the literature. It is comprehensive and based on health-related decisions. It represents the public interest
  Patient/family               Less common, only addresses the patient\'s and their family\'s costs
  Public/private health care   To identify and quantify all inputs used in the production of the service/procedure. Important to form the cost of illness

###### 

Comparison of findings on costs of PD in selected studies.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                      Country/Region         Year   *n*       Design     Costs studied   Perspective   Value/year\                                                                       Comments
                                                                                                                               US\$                                                                              
  ------------------------------------------- ---------------------- ------ --------- ---------- --------------- ------------- --------------------------------------------------------------------------------- ----------------------------------------------------------
  Yoritaka et al. \[[@B44]\]                  Japan                  2016   715       SPO        D               S             5,828                                                                             Direct cost

  Martínez-Martin et al., \[[@B45]\]          Spain                  2015   174       PO/BU      D/I             S             13,720.24/year 4                                                                  Magnitude of disease and quality of life

  Tamás et al. \[[@B39]\]                     Hungary                2014   110       PE/BU      D/I/OOP         S/CH          6,831                                                                             Costs of illness and quality of life

  Kowal et al. \[[@B22]\]                     USA                    2013   630,000   PE         D/I             S             22,800                                                                            Economic load current and projected (by 2050) in the USA

  Zhao et al. \[[@B19]\]                      Singapore              2013   195       PE/MK/BU   D/I             S             68,519 (over the lifetime period)                                                 Cost of illness

  Johnson et al. \[[@B41]\]                   USA                    2013   1,151     RE         D/I             CS            43,506 PDINST (cohort)                                                            Cost of illness x several cohorts

  Bhattacharjee and Sambamoorthi \[[@B29]\]   USA                    2013   350       RE         D/OOP           S             15,404                                                                            Cost of illness/over expenditure associated with PD

  Kaltenboeck et al. \[[@B23]\]               USA                    2012   25,577    RE         D               G             78,042 (ambulatory pac. PD)                                                       Survival rates and costs of patients of health programs

  Bach et al. \[[@B43]\]                      Germany                2012   1,449     PE         D/I             G             6.00 (2190) to 12.69 (4631.85)                                                    Cost of illness/drugs/comorbidities

  Lökk et al. \[[@B25]\]                      Sweden                 2012   4,163     PE/RE      D               S             9,333                                                                             Cost of illness/drugs

  Johnson et al. \[[@B20]\]                   USA                    2011   278       PO         I               S/CH/CS       569,393 (45 years), 188,590 (55), 35,496 (65), 2,451 (75) (from 40 to 79 years)   Indirect costs

  Jennum et al. \[[@B26]\]                    Denmark                2011   13,400    RE/PO      D/I             S             7,763                                                                             Cost of illness

  Zhao et al. \[[@B38]\]                      Singapore              2011   195       PE/BU      D/I/OOP         S             10,129                                                                            Cost of illness

  von Campenhausen et al. \[[@B47]\]          Europe (6 countries)   2011   486       PE/RE/BU   D/I/OOP         S             2,968 to 11,124                                                                   Cost of illness

  Winter et al. \[[@B30]\]                    Italy                  2010   70        PO/BU      D/I/OOP         S             19,574                                                                            Cost of illness/drugs

  Winter et al. \[[@B48]\]                    Germany                2010   145       PO/PE/BU   D/I/OOP         G             22,763                                                                            Cost of illness

  Winter et al. \[[@B49]\]                    Germany                2010   145/133   PE/RE      D/I             S             21,138 to 35,864                                                                  Cost of illness

  Winter et al. \[[@B32]\]                    Czech Rep.             2009   100       PE/RE/BU   D/I             S/CH/P        12,483                                                                            Cost of illness

  Winter et al. \[[@B37]\]                    Russia                 2009   100       PE/PO/BU   D/I             S/CH          5,935                                                                             Cost of illness

  Vargas et al. \[[@B42]\]                    Brazil                 2008   144       PE/PO/BU   IN              NA            NA                                                                                Resource use X incapacity

  McCrone et al. \[[@B33]\]                   UK                     2007   175       PE/RE      D/OOP           CS/P          19,861                                                                            Cost of illness

  Leibson et al. \[[@B35]\]                   USA                    2006   92        PE/RE      D               NA            Unclear                                                                           Cost of illness per groups

  Ragothaman et al. \[[@B36]\]                India                  2006   175       PE/PO      D               S             707                                                                               Cost of illness/direct costs

  Wang et al. \[[@B50]\]                      China                  2006   190       PE/RE/BU   D/I             S             925                                                                               Cost of illness

  Vossius et al. \[[@B31]\]                   Germany/Norway         2006   438       PE/RE/PO   D               S             2,389 (Germany), 1,620 (Norway)                                                   Cost of PD drugs

  Noyes et al. \[[@B27]\]                     USA                    2006   717       PE/RE      D/OOP           S/P           18,528                                                                            Cost of illness/drugs/medicare

  Cordato et al. \[[@B28]\]                   Australia              2006   12        PE/PO      D/I             S             5,380                                                                             Cost of illness

  Huse et al. \[[@B24]\]                      USA                    2005   20,016    PE/RE      D               CS            10,037                                                                            Cost of illness

  Spottke et al. \[[@B34]\]                   Germany                2005   145       PE/PO      D/I/OOP         S/G/P         22,723 ± 28,297                                                                   Cost of illness

  Cubo et al. \[[@B21]\]                      Spain                  2005   23,417    RE         Int.            G             NA                                                                                Years of life lost
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Notes: SPO = semiprospective; PO = prospective; BU = bottom-up; PE = prevalent, MK = Markov; RE = retrospective; D = direct cost; I = indirect cost; OOP = out-of-pocket; Int. = intangible; S = society; CH = human capital; CS = insurance companies; G = government; NA = not applicable; P = patient; PDINST = patients with PD institutionalized; Medicare = USA health care.

###### 

Most common variables found in the cost studies of Parkinson\'s disease.

  --------------------------------------------------------------------------------------------------------------------------------------------
  Patient/disease   Direct medical cost      Direct nonmedical cost             Indirect cost                         Out-of-pockets
  ----------------- ------------------------ ---------------------------------- ------------------------------------- ------------------------
  Age               Hospitalization          Ancillary therapy/rehabilitation   Retirement                            Transportation^*∗*^

  Gender            Pharmacotherapy\         Home Care^*∗*^                     Retirement premature                  Special food
                    (PD and comorbidities)                                                                            

  Marital status    Outpatient visit         Transportation^*∗*^                Sick leave                            Laundry

  Instruction       Diagnostics              Special equipment^*∗*^             Working days loss of the patient      Home Care^*∗*^

  Working status    Nursing home             Home modification^*∗*^             Working days loss of the caregivers   Caregivers

  Duration of PD                             Copayments^*∗*^                    Productivity loss                     Special equipment^*∗*^

  Comorbidities                                                                 Loss of leisure time                  Home modification^*∗*^

  H & Y stage^1^                                                                                                      Private health plans

  UPDRS^2^                                                                                                            Copayments^*∗*^

  PQD-39^3^                                                                                                            

  MMSE^4^                                                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------

^1^Hoehn & Yahr scale of disability/^2^Unified Parkinson\'s Disease Rating Scale/^3^Parkinson\'s Disease Questionnaire--39 (quality of life)/^4^Mini-Mental State Examination.

^*∗*^Variables that may be in more than one cost type.

[^1]: Academic Editor: Antonio Pisani
